UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Managing Perplexing Intracranial Lesions

International journal of radiation oncology, biology, physics, 2019-10, Vol.105 (2), p.244-244

2019

Volltextzugriff (PDF)

Nivolumab for the Treatment of Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma (nccRCC): A Single‐Institutional Experience and Literature Meta‐Analysis

The oncologist (Dayton, Ohio), 2020-03, Vol.25 (3), p.252-258

2020

Volltextzugriff (PDF)

Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.419-419

2024

Volltextzugriff (PDF)

Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN+PEM)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.433-433

2024

Volltextzugriff (PDF)

Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis

Journal of cancer research and clinical oncology, 2023-08, Vol.149 (9), p.5841-5852

2023

Volltextzugriff (PDF)

Burnout among early-career medical oncologists: A single-institution experience

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11015-11015

2022

Volltextzugriff (PDF)

Doxorubicin, paclitaxel, and cisplatin (ATP) for refractory germ cell tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17028-e17028

2023

Volltextzugriff (PDF)

A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4542-4542

2024

Volltextzugriff (PDF)

Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4610-TPS4610

2022

Volltextzugriff (PDF)

Management of Advanced Bladder Cancer: An Update

Journal of the advanced practitioner in oncology, 2018-05, Vol.9 (4), p.410-416

2018

Volltextzugriff (PDF)

A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy

Science translational medicine, 2022-04, Vol.14 (641), p.eabm6420

2022

Volltextzugriff (PDF)

Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16618-e16618

2023

Volltextzugriff (PDF)

Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.522-522

2023

Volltextzugriff (PDF)

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS745-TPS745

2023

Volltextzugriff (PDF)

Evaluation of immune exhaustion across the evolution of oligometastatic clear cell renal cell carcinoma using spatially resolved tissue immune profiling: Secondary analysis of a prospective trial

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.701-701

2023

Volltextzugriff (PDF)

Bilateral germ cell tumor of the testis (TGCT): Implications for a stem cell versus genetic origin of cancers

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.428-428

2023

Volltextzugriff (PDF)

Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4561-4561

2021

Volltextzugriff (PDF)

Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4605-4605

2024

Volltextzugriff (PDF)

Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.324-324

2021

Volltextzugriff (PDF)

Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract: The MD Anderson Cancer Center (MDACC) experience

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.630-630

2024

Volltextzugriff (PDF)

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.362-362

2024

Volltextzugriff (PDF)

Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4501-4501

2022

Volltextzugriff (PDF)

A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4612-TPS4612

2022

Volltextzugriff (PDF)

A retrospective analysis of carboplatin plus etoposide in patients with adrenal cortical carcinoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16591-e16591

2018

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(72)
Buchkapitel
(2)

Sprache

Englisch
(74)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Managing Perplexing Intracranial Lesions

Nivolumab for the Treatment of Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma (nccRCC): A Single‐Institutional Experience and Literature Meta‐Analysis

Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC)

Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN+PEM)

Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis

Burnout among early-career medical oncologists: A single-institution experience

Doxorubicin, paclitaxel, and cisplatin (ATP) for refractory germ cell tumors

A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)

Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy

Management of Advanced Bladder Cancer: An Update

A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy

Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV)

Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC)

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases

Evaluation of immune exhaustion across the evolution of oligometastatic clear cell renal cell carcinoma using spatially resolved tissue immune profiling: Secondary analysis of a prospective trial

Bilateral germ cell tumor of the testis (TGCT): Implications for a stem cell versus genetic origin of cancers

Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC)

Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO)

Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC)

Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract: The MD Anderson Cancer Center (MDACC) experience

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial

Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER

A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer

A retrospective analysis of carboplatin plus etoposide in patients with adrenal cortical carcinoma

Suchergebnisse filtern